HCPCS Code S0112: Cytarabine 500 mg billing and coverage guide

HCPCS Code S0112 is the Healthcare Common Procedure Coding System Level II code for cytarabine, 500 mg, used primarily by commercial payers and Medicaid managed care organizations to reimburse this oncology drug. Most denial patterns on S0112 claims trace back to three fixable mistakes: wrong payer (Medicare does not accept S-series codes), missing NDC attachment, or incorrect unit calculation. This guide covers the official descriptor, payer coverage rules, the S0112-versus-J9100 distinction, claim construction, and denial resolution for oncology billers and practice managers.

Found our content helpful?

Key Takeaways

HCPCS Code S0112 describes cytarabine 500 mg per dose, an antineoplastic agent billed by commercial and Medicaid MCO payers; Medicare uses J9100 instead.

S0112 and J9100 are not interchangeable: S0112 is per 500 mg and non-Medicare; J9100 is per 100 mg and Medicare-covered under Part B at ASP+6%.

Every S0112 claim requires an 11-digit NDC attachment in the correct qualifier-quantity format; missing NDC is the leading claim denial reason.

Pabau’s oncology claims management software automates drug code workflows, NDC attachment, and ERA-based denial tracking for practices billing S0112.

HCPCS Code S0112: Official Descriptor and Code Details

HCPCS Code S0112 is a Level II S-series code maintained by the Centers for Medicare & Medicaid Services (CMS) to identify cytarabine 500 mg for claims submission to non-Medicare payers. S-series codes (S0000-S9999) are temporary national codes developed for commercial payers and Medicaid; they are not recognized by Medicare for reimbursement purposes.

The table below summarizes the key reference data for HCPCS Code S0112.

What Does S0112 Cover? Drug Description and Clinical Context

Cytarabine (also called Ara-C or cytosine arabinoside) is an antineoplastic pyrimidine analogue used in the treatment of acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), non-Hodgkin lymphoma (NHL), and meningeal leukemia. It works by interfering with DNA synthesis in rapidly dividing cancer cells.

Clinical settings where S0112 is administered include hospital outpatient infusion centers, physician office infusion suites, and dedicated oncology infusion clinics. The drug is given intravenously or intrathecally depending on the regimen and indication.

• AML induction and consolidation: High-dose cytarabine regimens are a cornerstone of adult AML treatment protocols.
• ALL treatment: Used in combination chemotherapy regimens for both pediatric and adult ALL.
• NHL: Incorporated into salvage regimens such as R-DHAP and R-ESHAP.
• Meningeal disease: Intrathecal cytarabine addresses central nervous system involvement.

The 500 mg unit basis of S0112 means each billed unit represents a 500 mg dose increment. Practices billing a 1,000 mg dose would report two units (1,000 ÷ 500 = 2).

S0112 vs. J9100: Choosing the Right Cytarabine Code

S0112 and J9100 both describe cytarabine, but they serve different payers and use different units. Substituting one for the other is a billing error with audit risk.

The key decision rule: verify the patient’s primary payer before selecting the code. Medicare beneficiaries require J9100 regardless of supplemental coverage. Commercial and Medicaid MCO patients typically use S0112, but confirm with the plan’s formulary and HCPCS code lookup before billing.

Medicare and Medicaid Coverage for HCPCS Code S0112

Medicare does not reimburse S0112. The Centers for Medicare & Medicaid Services designates S-series codes as non-Medicare by design; CMS uses J-series codes for physician-administered drugs under Part B. Submitting S0112 to Medicare results in an automatic non-covered denial.

• Medicare Part B: Use J9100 (cytarabine, 100 mg) for Medicare beneficiaries. Reimbursement is at ASP+6% under the CMS Physician Fee Schedule.
• Commercial payers: Most commercial plans accept S0112. Reimbursement is typically pegged to the contracted rate, wholesale acquisition cost (WAC), or average wholesale price (AWP) – specific rates vary by contract and are updated periodically.
• Medicaid fee-for-service: State Medicaid programs vary significantly. Many states do not recognize S-series codes and require J9100 instead. Always verify with the state’s Medicaid agency or managed care organization before billing.
• Medicaid MCOs: Some managed care organizations within state Medicaid programs do accept S0112. Coverage rules are plan-specific and may change with contract year.

Check payer eligibility and plan coverage before every claim. A single-digit code error (S0112 vs. J9100) on a Medicare account is the most common avoidable denial on cytarabine claims.

Prior Authorization Requirements for S0112

Prior authorization (PA) requirements for S0112 vary by payer and plan year. No universal rule applies, but oncology drug codes routinely require PA under commercial plans.

Common PA criteria payers apply to cytarabine claims:

• Oncology clinical criteria: Diagnosis must align with an approved indication (AML, ALL, NHL, or meningeal leukemia) supported by pathology or staging documentation.
• Diagnosis code linkage: The ICD-10-CM code on the PA request must match the diagnosis on the claim.
• Step therapy: Some plans require documentation that first-line alternatives were considered or attempted where clinically appropriate.
• Formulary placement: Cytarabine is a generic chemotherapy agent; most plans include it on formulary, but some MCOs require specialty pharmacy authorization for high-dose regimens.
• Regimen documentation: Include the named treatment protocol (e.g., HiDAC, DHAP) with the PA request to demonstrate clinical appropriateness.

Submit PA requests before the first infusion date. Most commercial plans require 3-5 business days for oncology PA review, though urgent requests may be expedited.

How to Bill S0112: Units, NDC Reporting, and Claim Line Setup

Accurate claim construction for S0112 requires three elements: correct unit calculation, proper NDC attachment, and linkage to the right administration code. Missing any one of these produces a denial.

Use Pabau’s oncology claims management tools to automate NDC attachment and unit verification before submission.

Unit calculation

Each S0112 unit equals 500 mg. Divide the total milligrams administered by 500 to determine the number of units to bill. Always round to the nearest whole unit per payer instructions; do not bill fractional units unless the payer’s fee schedule explicitly permits it.

NDC attachment format

CMS requires an 11-digit NDC on all drug HCPCS claims. The standard loop/segment format on electronic 837P claims is: qualifier N4, followed by the 11-digit NDC (no hyphens), then the unit qualifier (UN for each unit, ML for milliliters, GR for grams), then the quantity dispensed.

On paper CMS-1500 claims, enter the NDC in the shaded area of Box 24, prefixed with “N4.” A missing or malformed NDC is the single most common denial trigger for S0112. Verify each drug lot’s NDC against the pharmacy dispensing record, not from memory.

Administration code linkage

S0112 is the drug code only. Always pair it on the same claim with the appropriate infusion administration CPT code (typically 96413 for initial chemotherapy infusion, 96415 for each additional hour). The administration code and the drug code must share the same date of service. Payers bundle the two; submitting the drug code alone without an administration code produces a technical denial.

ICD-10-CM Diagnosis Codes Commonly Reported with HCPCS Code S0112

Every S0112 claim must be supported by an ICD-10-CM diagnosis code that establishes medical necessity for cytarabine. The diagnosis must reflect an approved oncology indication. The table below lists the most commonly paired codes.

Code to the highest specificity available in the medical record. Submitting a nonspecific diagnosis (e.g., an unspecified leukemia code when the record confirms AML) is a documentation gap that can trigger a medical necessity review or denial. Refer to billing compliance requirements for guidance on linking diagnosis codes to drug claims correctly.

Common Claim Denial Reasons for S0112 and How to Resolve Them

Most S0112 denials fall into a small number of repeating patterns. Recognizing the remark code on the remittance advice points directly to the corrective action needed. Solid denial management strategies reduce rework on these claims significantly.

Track denial patterns by remark code across all cytarabine claims. Refer to the full list of denial codes in medical billing for remark code definitions and resolution pathways.

Stop chasing S0112 denials manually

Pabau’s claims management tools help oncology practices automate NDC attachment, unit verification, and ERA-based denial tracking so you spend less time on rework and more time on patient care.

Book a demo

Documentation Requirements to Support S0112 Claims

Payers auditing cytarabine claims look for a specific set of documentation elements. Each missing element maps to a denial risk. Strong medical billing workflows start with documentation standards built into the infusion nursing workflow, not reconciled at the billing desk afterward.

• Oncologist order: Signed, dated order specifying the drug name, dose, route, and frequency. Must predate the infusion date of service.
• Diagnosis and staging: Pathology report or clinical note confirming the ICD-10 diagnosis. Leukemia and lymphoma codes require specificity (e.g., C92.00 vs. C92.01).
• Regimen name and cycle: Document the named protocol (HiDAC, R-DHAP, etc.) and cycle number to support medical necessity in an audit.
• Drug lot number and NDC: Pharmacy dispense record must show the exact NDC linked to the units administered. This is the source document for NDC attachment on the claim.
• Dose administered and date of service: Nursing infusion note must confirm the total milligrams infused and the start/stop times to support the administration CPT codes.
• Route of administration: IV versus intrathecal matters for both clinical safety and billing; document explicitly in the nursing note.

Tie each documentation element to its downstream billing impact. An absent lot number means no valid NDC; no valid NDC means an automatic denial on the drug claim line.

S0112 Reimbursement Rates and Pricing Considerations

Reimbursement for HCPCS Code S0112 under commercial payers is generally negotiated at the contract level, not set by a universal fee schedule the way Medicare’s ASP+6% pricing works for J9100.

Understanding how each pricing methodology works helps practices evaluate contract adequacy and identify underpayments on cytarabine claims.

Because S0112’s S-series status means no published Medicare payment benchmark applies, practices should reference the NLM HCPCS Level II API for current code data and negotiate commercial rates against WAC or AWP benchmarks where contracts permit. Drug pricing data is updated periodically; any rate figures cited internally should be treated as point-in-time estimates.

Conclusion

HCPCS Code S0112 is the correct cytarabine code for commercial and Medicaid MCO billing, but the margin for error on claim construction is narrow. Getting payer selection, unit calculation, NDC format, and diagnosis linkage right on every claim is the difference between clean first-pass reimbursement and a denial queue that absorbs hours of staff time.

Pabau’s claims management software supports oncology billing workflows with built-in code validation, NDC attachment, and ERA-driven denial tracking. To see how it handles S0112 and other drug HCPCS codes end to end, book a demo.

Continue your research

Need a guide to the full HCPCS billing framework? Medical billing workflows explains how HCPCS drug codes fit into the end-to-end claims process.

Getting repeated CO-16 or CO-50 remittance codes? Denial codes in medical billing covers remark code definitions and step-by-step appeal workflows.

Want to reduce compliance risk on drug claims? Billing compliance requirements outlines documentation and audit-readiness standards for specialty drug billing.

Frequently Asked Questions